Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bioxcel Therapeutics Inc (NQ: BTAI )

0.5090 -0.0616 (-10.80%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bioxcel Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
What's Next: BioXcel Therapeutics's Earnings Preview
Via Benzinga
BTAI Stock Earnings: BioXcel Therapeutics Beats EPS, Beats Revenue for Q2 2024
BTAI stock results show that BioXcel Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
BioXcel Therapeutics' Approved Drug For Bipolar Disorders/Schizophrenia Shows No Evidence Of Worsening Or Withdrawal In Post-Marketing Study
BioXcel Therapeutics shares topline results from an Igalmi (dexmedetomidine) sublingual film study. The 180 mcg dose demonstrated favorable safety and efficacy in reducing agitation symptoms. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth checking out on Tuesday as we get into all of the hottest news worth reading about this morning! 
Via InvestorPlace
BioXcel Therapeutics's Earnings Outlook
Via Benzinga
Why BioXcel Therapeutics Shares Are Falling Today
BioXcel Therapeutics sees a dip in shares as it launches a $60 million public offering to fund clinical trials and corporate needs. 
Via Benzinga
Earnings Scheduled For November 14, 2024
Via Benzinga
BTAI Stock Earnings: BioXcel Therapeutics Misses EPS, Beats Revenue for Q1 2024
BTAI stock results show that BioXcel Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
AI Surge Has Ended: All 7 AI Stock Categories Declined This Week
From no AI category losses in February, to 3 drops in March - now all 7 fell this week, clearly indicating that that the surge in AI stock prices that began back on October 31st is, indeed, over. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Six Of Seven AI Stock Categories Increased This Week
All but one of the 7 artificial intelligence stock categories that I analyze weekly increased in value this week. But two categories are still down MTD, suggesting that the surge in the artificial... 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode
Bullish speculators could have their opportunity to blow up the bears with these short-squeeze stocks to buy. 
Via InvestorPlace
Earnings Scheduled For March 12, 2024
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter. 
Via Benzinga
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
Grand View Research says the global 
Via Talk Markets
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics
The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Leading The Charge: Tonix Pharmaceuticals And The Future Of CNS Therapeutics
Via Get News
Why BioXcel Therapeutics Shares Are Rising Tuesday
BioXcel Therapeutics shares surge 25.1% as the company terminates its proposed public offering and shifts focus to upcoming FDA meeting and Phase 3 trial. 
Via Benzinga
Exposures Product Safety
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
From FN Media Group LLC
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
BIOXCEL ALERT: Bragar Eagel & Squire, P.C. is Investigating BioXcel Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Take-Two Interactive Software, Inc. (NASDAQ: TTWO) fell sharply during Friday’s session following third-quarter results. 
Via Benzinga
Why Is CleanSpark (CLSK) Stock Up 27% Today?
CleanSpark stock is rising higher on Friday as investors in CLSK shares celebrate the company's positive Q1 earnings report. 
Via InvestorPlace
S&P 500 Tops 5,000; PepsiCo Posts Upbeat Earnings
U.S. stocks traded mixed this morning, with the S&P 500 topping the 5,000 mark on Friday. Following the market opening Friday, the Dow traded down 0.05% to 38,706.33 while the NASDAQ rose 0.32% to... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is BioXcel Therapeutics (BTAI) Stock Down 26% Today?
BioXcel Therapeutics stock is falling on Friday after the company announced plans for a proposed public offering of BTAI shares. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.